Mycosis fungoides primary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
- There are no established measures for the secondary prevention of mycosis fungoides but recommended that effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.
Primary Prevention
- There are no established risk factors for mycosis fungoides.
- The risk factors in the development of mycosis fungoides is environmental and occupational exposure include [1][2][3]
- Bacterial infection of the skin
- Long term exposure to chemicals
- Smoking
- Medications
- Long term sun exposure
- Viral infections (Human T lymphotropic virus type I)
References
- ↑ A. S. Whittemore, E. A. Holly, I. M. Lee, E. A. Abel, R. M. Adams, B. J. Nickoloff, L. Bley, J. M. Peters & C. Gibney (1989). “Mycosis fungoides in relation to environmental exposures and immune response: a case-control study”. Journal of the National Cancer Institute. 81 (20): 1560–1567. PMID 2795681. Unknown parameter
|month=ignored (help) - ↑ Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Röupe G, Vahlne A (July 1991). “Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides”. Science. 253 (5017): 317–20. PMID 1857968.
- ↑ S. K. Ghosh, J. T. Abrams, H. Terunuma, E. C. Vonderheid & E. DeFreitas (1994). “Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma”. Blood. 84 (8): 2663–2671. PMID 7522638. Unknown parameter
|month=ignored (help)
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH